FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington,	DС	20549
rvasiliigion,	D.C.	20040

Check this box if no longer subject
to Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL							
OMB Number: 3235-0287							
Estimated average burden							
hours per response: 0.							

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Maroney Dawn Christine				2. Issuer Name and Ticker or Trading Symbol Alignment Healthcare, Inc. [ ALHC ]								5.	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner					wner		
(Last)	(Fir	st) (M	Middle	e)	3. Date of Earliest Transaction (Month/Day/Year) 03/13/2024								X	Officer (give title below)  President, N			Other (s below) arkets	вресіту 		
SUITE 1600					4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street) ORANG	(Street) ORANGE CA 92868														X Form filed by One Reporting Person  Form filed by More than One Reporting  Person					
(City) (State) (Zip)							Rule 10b5-1(c) Transaction Indication  Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to													
satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.  Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																				
1. Title of Security (Instr. 3)  2. Transaction Date (Month/Day/Ye				2A. Deemed Execution Da		ned on Date	ned 3. Transaction Code (Instr.		action	4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and		d (A) or	5. An Secu Bene Owne		ount of ities icially d Following	For (D) ( Indi	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
					(	Code	v .	Amount (A) or (D)		Price		Transa	Reported (I ransaction(s) Instr. 3 and 4)		1150. 4)	(msu. 4)				
Common Stock 03/13/202					.4			A		206,890(1)	A	\$0.0	00	2,036,898			D			
Common Stock 03/15/202					:4			S		21,537(2)	D	\$4.89	11(3)	2,015,361			D			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Exe if an	Deemed cution Date, ly nth/Day/Year)	Code 8)	Transaction of Code (Instr. Derivative			Expiration Date (Month/Day/Year)			Amount of D Securities S		Der Sec	rice of ivative urity Securities Beneficially Owned Following Reported Transactio (Instr. 4)		y	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	

## **Explanation of Responses:**

- 1. Represents (i) 130,000 restricted stock units, each restricted stock unit representing the right to receive one share of Common Stock of the Company, that will vest 25% on each of the first four anniversaries of the grant date, subject to the reporting person's continued service to the Company as of the applicable vesting date; (ii) 41,000 fully vested shares of Common Stock granted as a discretionary award to the reporting person by the Board of Directors; and (iii) 35,890 fully vested shares of Common Stock granted in lieu of cash settlement of the annual incentive award earned by the reporting person for the 2023 fiscal year.
- 2. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This transaction does not represent a discretionary trade by the reporting person.
- 3. The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from \$4.77 to \$5.06. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range.

## Remarks:

/s/ Christopher J. Joyce, as Attorney-in-Fact, for Dawn C. 03/15/2024 Maroney

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.